On August 22, 2024, the FDA approved and authorized updated 2024-25 mRNA COVID-19 vaccines to better protect against currently circulating variants. The updated vaccines include Spikevax (Moderna) and Comirnaty (Pfizer), fully FDA-approved for individuals 12 years and older, and the Moderna and Pfizer-BioNTech COVID-19 vaccines, authorized for emergency use for individuals ages 6 months through 11 years old. On August 30, 2024, the FDA additionally granted emergency use authorization for the updated 2024-2025 Novavax COVD-19 vaccine for individuals ages 12 years and older.
Onco360® Has Been Selected as a National Specialty Pharmacy for VORANIGO®(vorasidenib)
Onco360® has been selected by Servier Pharmaceuticals as a specialty pharmacy partner for VORANIGO® (vorasidenib), which is approved for the treatment of adults and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma and a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection.
Guide to Managing Payment & Regulatory Risk: MDS 1.19.1
The balancing act of managing payments and regulatory risk requires flexibility, agility, and planning. This new guide, written in partnership with Leah Klusch of The Alliance Training Center, offers insights, tips, and updates to help you meet the challenges and take advantage of the opportunities.
Medicaid Access Rule: What I/DD Providers Need to Know
This article answers five key questions about the Ensuring Access to Medicaid Services rule, including its meaning, requirements, and potential impact on I/DD providers.
